Synthesis and initial tumor affinity testing of iodine-123 labelled EGFR-affine agents as potential imaging probes for hormone-refractory prostate cancer

European Journal of Medicinal Chemistry

Volumn 45, Issue 9, 2010, Pages 3780-3786

  Fozing, Thierry ^a   Scheuer, Claudia ^a   Samnick, Samuel ^b  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

EGFR expressing cancer; Prostate cancer; Radioiodination; Radiopharmaceuticals; SPECT

Indexed keywords

2 AMINOBICYCLO[2.2.1]HEPTANE 2 CARBOXYLIC ACID; 4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE I 123; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR; GEFITINIB; IMMUNOGLOBULIN G2A ANTIBODY; IODINE 123; MAB425; MONOCLONAL ANTIBODY 425 I 123; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CELL STRAIN LNCAP; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG BINDING; DRUG INHIBITION; DRUG LABELING; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UPTAKE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOLECULAR IMAGING; MOUSE; NONHUMAN; NUDE RAT; OUTCOME ASSESSMENT; PHOTON EMISSION TOMOGRAPHY; PROGNOSIS; PROSTATE CARCINOMA; PROTEIN EXPRESSION; RADIOACTIVITY; RADIOCHEMISTRY; RAT; REACTION TIME; SCINTILLATION CAMERA; TUMOR CELL; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HORMONES; HUMANS; IODINE RADIOISOTOPES; MALE; MICE; MOLECULAR IMAGING; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TOMOGRAPHY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77955555615     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2010.05.027     Document Type: Article

References (26)

1. E.D. Crawford Epidemiology of prostate cancer Urology 62 6 2003 3 12
2. A. Jemal, R. Siegel, and E. Ward Cancer statistics, 2008 CA Cancer J. Clin. 58 2008 71 96
3. S.A. Brassell, I.L. Rosner, and D.G. McLeod Update on magnetic resonance imaging, ProstaScint, and novel imaging in prostate cancer Curr. Opin. Urol. 15 3 2005 163 166
4. E. Gronau, M. Goppelt, R. Harzmann, and D. Weckermann Prostate cancer relapse after therapy with curative intention: a diagnostic and therapeutic dilemma Onkologie 28 6-7 2003 361 366
5. M.R. Hersh, E.L. Knapp, and J. Choi Newer imaging modalities to assess tumor in the prostate Cancer Control 11 2004 353 357
6. 11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer Eur. J. Nucl. Med. Mol. Imaging 35 1 2008 18 23
7. 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer Cancer Res. 61 1 2001 110 117
8. C. Greco, G.L. Cascini, and O. Tamburrini Is there a role for positron emission tomography imaging in the early evaluation of prostate cancer relapse? Prostate Cancer Prostatic Dis. 11 2 2008 121 128
9. M. Farsad, R. Schiavina, A. Franceschelli, F. Sanguedolce, P. Castellucci, A. Bertaccini, E. Brunocilla, F. Manferrari, S. Concetti, M. Garofalo, C. Rocca, M. Borghesi, R. Franchi, S. Fanti, C. Nanni, and G. Martorana Positron-emission tomography in imaging and staging prostate cancer Cancer Biomark 4 4-5 2008 277 284
10. 11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer J. Clin. Oncol. 24 16 2006 2513 2519
11. 123I]TIC(OH) for targeting prostate cancer Appl. Radiat. Isot. 64 2006 563 569
12. 123I]iodo-L-1,2,3,4-tetrahydro-7- hydroxyiso-quinoline-3-carboxylic acid as an imaging agent for prostate cancer in experimental models of human prostate cancer Nucl. Med. Biol. 34 1 2007 99 107
13. G.O. Hellawell, and S.F. Brewster Growth factors and their receptors in prostate cancer BJU Int. 89 3 2002 230 240
14. P.J. Russell, S. Bennett, and P. Stricker Growth factor involvement in progression of prostate cancer Clin. Chem. 44 4 1998 705 723
15. S. Yano, M. Yamaguchi, and R.P. Dong EGFR tyrosine kinase inhibitor "Gefitinib (Iressa)" for cancer therapy Nippon Yakurigaku Zasshi 122 6 2003 491 497
16. E. Hernes, S.D. Fossa, A. Berner, B. Otnes, and J.M. Nesland Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence Br. J. Cancer 90 2004 449 454
17. G. Di Lorenzo, G. Tortora, F.P. D'Armiento, G. De Rosa, S. Staibano, R. Autorino, M. D'Armiento, M. De Laurentiis, S. De Placido, G. Catalano, A.R. Bianco, and F. Ciardiello Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer Clin Cancer Res. 8 11 2002 3438 3444
18. 18F- Fluoropropionic Acid as a PET Imaging agent for prostate cancer J. Nucl. Med. 50 2009 1709 1714
19. 18F]fluoro-2- deoxy-d-glucose in human pancreatic carcinoma xenografts and in inflammation models Nucl. Med. Biol. 32 2005 137 145
20. A. Levitzki, and A. Gazit Tyrosine kinase inhibition: an approach to drug development Science 267 5205 1995 1782 1788
21. S. Eguchi, K. Numaguchi, H. Iwasaki, T. Matsumoto, T. Yamakawa, H. Utsunomiya, E.D. Motley, H. Kawakatsu, K.M. Owada, Y. Hirata, F. Marumo, and T. Inagami Calcium-dependent epidermal growth factor receptor transactivation mediates the angiotensin II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells J. Biol. Chem. 273 15 1998 8890 8896
22. T.S. Quang, and L.W. Brandy Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas Int. J. Radiat. Oncol. Biol. Phys. 58 2004 972 975
23. D.W. Fry, A.J. Kraker, and A. McMichael A specific inhibitor of the epidermal growth factor receptor tyrosine kinase Science 265 1994 1093 1095
24. V. Chandregowda, A.K. Kush, and G. Chandrasekara Reddy Synthesis and in vitro antitumor activities of novel 4-anilinoquinazoline derivatives Eur. J. Med. Chem. 44 2009 3046 3055
25. A. Lüth, and W. Löwe Syntheses of 4-(indole-3-yl)quinazolines: a new class of epidermal growth factor receptor tyrosine kinase inhibitors Eur. J. Med. Chem. 43 2008 1478 1488
26. B.C. Fuchs, and B.P. Bode Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin. Cancer Biol. 15 2005 254 266